Literature DB >> 8221573

Regional heterogeneity in the DNA content of human gliomas.

S W Coons1, P C Johnson.   

Abstract

BACKGROUND: Regional heterogeneity causes significant errors in the histologic classification and grading of gliomas, but little is known about its implications for other modalities. Attempts to predict glioma behavior using flow cytometry (FCM) have yielded contradictory results, possibly due to regional heterogeneity in DNA content, a recognized phenomenon that has not been evaluated systematically.
METHODS: The authors used FCM to analyze the DNA content of 353 regions from 18 resected human gliomas. Five to 60 regions were sampled from each tumor, and the topographic relationships of ploidy, proliferative activity (S-phase fraction [SPF]), and histologic features were established.
RESULTS: Most tumors demonstrated heterogeneity among regions in the number and relative sizes of aneuploid populations and/or proliferative activity. The degree of heterogeneity increased with tumor grade. Heterogeneity in histologic features, ploidy, and proliferative activity appeared to vary independently, except for a significant association between the presence of mitotic figures and the SPF of individual regions (P < 0.0001). The clustering of regions with similar percentages of aneuploid cells supported the concept of local clonal expansion.
CONCLUSIONS: Gliomas express significant regional heterogeneity in ploidy and proliferative activity and this will have an adverse effect on the usefulness of their analysis. However, the independent variation of ploidy, proliferative activity, and histologic features suggests that the use of multiple analyses may allow more accurate prediction of glioma patient survival. Regional heterogeneity appears be a fundamental property of malignant gliomas; systematic studies to determine its effects on the diagnostic usefulness of other new methods used to evaluate gliomas are indicated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8221573     DOI: 10.1002/1097-0142(19931115)72:10<3052::aid-cncr2820721030>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

1.  ACP Best Practice No 158. Neuropathology.

Authors:  W R Timperley
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

Review 2.  Proliferation markers in tumours: interpretation and clinical value.

Authors:  P J van Diest; G Brugal; J P Baak
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

3.  Extensive intra-tumor heterogeneity in primary human glial tumors as a result of locus non-specific genomic alterations.

Authors:  A Misra; P Chattopadhyay; A K Dinda; C Sarkar; A K Mahapatra; S E Hasnain; S Sinha
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

4.  Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging.

Authors:  Osamu Manabe; Naoya Hattori; Shigeru Yamaguchi; Kenji Hirata; Kentaro Kobayashi; Shunsuke Terasaka; Hiroyuki Kobayashi; Hiroaki Motegi; Tohru Shiga; Keiichi Magota; Noriko Oyama-Manabe; Ken-ichi Nishijima; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-03       Impact factor: 9.236

Review 5.  Toward an Ising model of cancer and beyond.

Authors:  Salvatore Torquato
Journal:  Phys Biol       Date:  2011-02-07       Impact factor: 2.583

6.  Proliferative activity and prognosis of low-grade astrocytomas.

Authors:  D Schiffer; P Cavalla; A Chiò; P Richiardi; M T Giordana
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

7.  Lectin histochemistry of astrocytic tumors and in vitro characterization of lectin-induced modifications on the proliferation of the SW1088, U373 and U87 human astrocytic cell lines.

Authors:  I Camby; I Salmon; R De Decker; J L Pasteels; J Brotchi; A Danguy; R Kiss
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

Review 8.  Oligodendrogliomas: clinicopathological correlations.

Authors:  J M Kros
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

9.  Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.

Authors:  Jonathon F Parkinson; Helen R Wheeler; Adele Clarkson; Catriona A McKenzie; Michael T Biggs; Nicholas S Little; Raymond J Cook; Marinella Messina; Bruce G Robinson; Kerrie L McDonald
Journal:  J Neurooncol       Date:  2007-11-15       Impact factor: 4.130

10.  Radiogenomics to characterize regional genetic heterogeneity in glioblastoma.

Authors:  Leland S Hu; Shuluo Ning; Jennifer M Eschbacher; Leslie C Baxter; Nathan Gaw; Sara Ranjbar; Jonathan Plasencia; Amylou C Dueck; Sen Peng; Kris A Smith; Peter Nakaji; John P Karis; C Chad Quarles; Teresa Wu; Joseph C Loftus; Robert B Jenkins; Hugues Sicotte; Thomas M Kollmeyer; Brian P O'Neill; William Elmquist; Joseph M Hoxworth; David Frakes; Jann Sarkaria; Kristin R Swanson; Nhan L Tran; Jing Li; J Ross Mitchell
Journal:  Neuro Oncol       Date:  2016-08-08       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.